Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen

Cited by papers we hold 5

• Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials · 2023
  No notice
• Neoantigens: promising targets for cancer therapy · 2023
  No notice
• A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy · 2022
  No notice
• Mutant p53 in cancer: from molecular mechanism to therapeutic modulation · 2022
  No notice
• Mutant p53 in Cancer Progression and Targeted Therapies · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.